UQ1 Stock Overview
Develops treatments for patients suffering from rare and other devastating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.66 |
| 52 Week High | US$16.66 |
| 52 Week Low | US$3.30 |
| Beta | 0.86 |
| 1 Month Change | 199.98% |
| 3 Month Change | 291.51% |
| 1 Year Change | 178.51% |
| 3 Year Change | -7.21% |
| 5 Year Change | -73.03% |
| Change since IPO | 30.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| UQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 13.6% | 3.1% | 0.5% |
| 1Y | 178.5% | -13.8% | 7.2% |
Return vs Industry: UQ1 exceeded the German Biotechs industry which returned -14.5% over the past year.
Return vs Market: UQ1 exceeded the German Market which returned 7% over the past year.
Price Volatility
| UQ1 volatility | |
|---|---|
| UQ1 Average Weekly Movement | 29.0% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UQ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UQ1's weekly volatility has increased from 21% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 480 | Matt Kapusta | www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
uniQure N.V. Fundamentals Summary
| UQ1 fundamental statistics | |
|---|---|
| Market cap | €828.87m |
| Earnings (TTM) | -€229.71m |
| Revenue (TTM) | €27.42m |
29.8x
P/S Ratio-3.6x
P/E RatioIs UQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UQ1 income statement (TTM) | |
|---|---|
| Revenue | US$28.59m |
| Cost of Revenue | US$182.66m |
| Gross Profit | -US$154.08m |
| Other Expenses | US$85.43m |
| Earnings | -US$239.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.91 |
| Gross Margin | -538.97% |
| Net Profit Margin | -837.80% |
| Debt/Equity Ratio | 856.0% |
How did UQ1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 17:59 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
uniQure N.V. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Madhu Kumar | B. Riley Securities, Inc. |